

## Technology Advisory Committee C Interests Register

### Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments [ID3943]

Publication Date: 31 January 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	Committee Member	Financial – indirect	Ms Thurgar has just started a project where she will be reviewing a global model for BREXU-CEL (Kite) in mantle cell lymphoma (MCL). MCL is a form of NHL although distinct from DLBCL.	18/10/2023	It was agreed that Ms Thurgar's declaration would not prevent her from participating in discussions on this appraisal.
Dr Kate Ren	Committee Member	Financial – indirect	Dr Ren provided statistical methodology consultancy service for comparator company Pfizer for an unrelated treatment in an unrelated disease area (tofacitinib for moderate to severe ulcerative colitis).	18/10/2023	It was agreed that Dr Ren's declaration would not prevent her from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee Member	Financial – indirect	Dr Nicholas has attended paid advisory boards for Roche in an unrelated disease area (multiple sclerosis).	31/10/2023	It was agreed that Dr Nicholas' declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Cathy Burton	Clinical Expert	Direct – financial	Dr Burton has received funding from Roche, BMS and Kite for advisory boards, honoraria for talks and support to attend conferences.	19/06/2023	It was agreed that Dr Burton's declaration would not prevent her from providing expert advice to the committee.
		Direct – non-financial	Dr Burton is a Trustee of Lymphoma Action.		
Dr Andrea Kuhn	Clinical Expert	Direct - financial	Dr Kuhn has received conference support and honoraria from Kite and has attended advisory boards for Gilead, Roche and BMS.	20/06/2023	It was agreed that Dr Kuhn's declaration would not prevent her from providing expert advice to the committee.